Newsroom

NEW YORK--(BUSINESS WIRE)--Debevoise & Plimpton LLP has secured affirmance from the U.S. Court of Appeals for the Second Circuit of its 2023 summary judgment win on behalf of YPF S.A., the largest energy producer in the Republic of Argentina – defeating claims for more than $16 billion in damages and interest. This is a landmark win for YPF, affirming the dismissal of a case that has been pending in S.D.N.Y since 2015. The Second Circuit fully affirmed the District Court’s holding that YPF...

LOS ANGELES--(BUSINESS WIRE)--YRD Investors Have Opportunity to Join Yiren Digital Ltd. Fraud Investigation with the Schall Law Firm...

LOS ANGELES--(BUSINESS WIRE)--PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm...

LOS ANGELES--(BUSINESS WIRE)--PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm...

大阪（日本）＆ ケンブリッジ（マサチューセッツ州）--(BUSINESS WIRE)--1日1回投与の利便性を備えた経口薬であるザソシチニブによる、迅速かつ持続的な皮膚症状の改善効果および乾癬治療を変革する可能性を示唆した臨床試験結果の発表について...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Atopic dermatitis is the most common inflammatory skin diso...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm....